Regeneron Pharmaceuticals (XTRA:RGO) - Cotización, noticias y análisis

Resumen de acción RGO

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

Acerca de la empresa

RGO fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	2/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 52.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 9.78%

Análisis de riesgos

Acciones altamente ilíquidas

Competidores de Regeneron Pharmaceuticals, Inc.

Biotest

XTRA:BIO3

€1.4b

Merck KGaA

XTRA:MRK

€68.8b

Formycon

XTRA:FYB

€770.0m

CSL

ASX:CSL

AU$135.1b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Regeneron Pharmaceuticals
Historical stock prices
Current Share Price	US$766.50
52 Week High	US$807.00
52 Week Low	US$632.00
Beta	0.16
1 Month Change	0%
3 Month Change	0.065%
1 Year Change	14.42%
3 Year Change	72.29%
5 Year Change	n/a
Change since IPO	7,595.78%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	RGO	DE Biotechs	Mercado DE
7D	0%	-2.9%	1.9%
1Y	14.4%	-25.4%	5.9%

Rentabilidad vs. Industria: RGO superó al sector German Biotechs , que obtuvo un rendimiento del -21.1% el año pasado.

Rentabilidad vs. Mercado: RGO superó al mercado German, que obtuvo un rendimiento del -0.3% el año pasado.

Volatilidad de los precios

Is RGO's price volatile compared to industry and market?
RGO volatility
RGO Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: RGO no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de RGO en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1988	12,463	Leonard Schleifer	www.regeneron.com

Resumen de fundamentos de Regeneron Pharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de Regeneron Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de RGO
Capitalización bursátil	€91.70b
Beneficios(TTM)	€3.67b
Ingresos (TTM)	€12.05b

25.0x

Ratio precio-beneficio (PE)

7.6x

Ratio precio-ventas (PS)

¿Está RGO sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de RGO
Ingresos	US$13.10b
Coste de los ingresos	US$6.14b
Beneficio bruto	US$6.95b
Otros gastos	US$2.96b
Beneficios	US$3.99b

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

Feb 02, 2024

Beneficios por acción (BPA)	37.53
Margen bruto	53.09%
Margen de beneficio neto	30.47%
Ratio deuda/patrimonio	8.0%

¿Cómo se ha desempeñado RGO a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción RGO

Recompensas

Análisis de riesgos

Competidores de Regeneron Pharmaceuticals, Inc.

XTRA:BIO3

€1.4b

XTRA:MRK

€68.8b

XTRA:FYB

€770.0m

ASX:CSL

AU$135.1b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Recent updates

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Announces Clinical Data from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Regeneron Pharmaceuticals, Inc.

25.0x

7.6x

Beneficios e Ingresos